1. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma
by Shaji K. Kumar, Betsy LaPlant, Wee Joo Chng, Jeffrey Zonder, Natalie Callander, Rafael Fonseca, Briant Fruth, Vivek Roy, Charles Erlichman, and A. Keith Stewart
Blood
Volume 125(3):
January 15, 2015
©2015 by American Society of Hematology

2. The distribution of all adverse events seen in the trial, which were considered at least possibly related to the study drug administration and seen in ≥2 patients across the study.
The distribution of all adverse events seen in the trial, which were considered at least possibly related to the study drug administration and seen in ≥2 patients across the study.
Shaji K. Kumar et al. Blood 2015;125:
©2015 by American Society of Hematology

3. Monoclonal protein response to treatment with dinaciclib.
Monoclonal protein response to treatment with dinaciclib. (A) Waterfall plot of the serum M protein responses among patients with a measurable M protein on serum protein electrophoresis at study entry. (B) Waterfall plot limited to patients with 24-hour urine M spike as measurable disease at study entry.
Shaji K. Kumar et al. Blood 2015;125:
©2015 by American Society of Hematology